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Eosinophilic Asthma
Bushra Mubarak, Huma Shakoor and Fozia Masood
Abstract
Eosinophilic asthma is known as a main phenotype of asthma classified on the 
basis of immune cells involved in inflammatory response in the respiratory airway. 
Eosinophilic asthma can be related to increased severity of asthma, allergic sensi-
tization, adult onset, and increased resistance to corticosteroids. The prevalence 
of eosinophilic asthma is 32–40% among asthmatic patients. Different cells and 
cytokines are involved in its pathogenesis including eosinophil, mast cells, type 
2 helper T cells, innate lymphoid cells, IL-4, IL-5, and IL-13. Eosinophil count in 
induced sputum and bronchoalveolar lavage is the yardstick for recognizing and 
distinguishing eosinophilic asthma from non-eosinophilic asthma, while various 
tests which are noninvasive such as fractional exhaled nitric oxide and periostin are 
arising as possible substitutes. Novel and advanced therapies new and advanced 
therapies and more convenient biological drugs, Leads to high requirement for 
particular endotype- and phenotype-related treatment plans. Identification and 
knowledge of the specific pathophysiology of eosinophilic asthma have great 
association with disease management and chances for better patient prognosis.
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1. Introduction
Asthma is a Greek word which means “labored breathing.” Asthma is a common 
disease which is characterized by reversible airway inflammation, chronic airway 
blockage, hyperresponsiveness, wheezing, and cough arising spontaneously and 
in reaction to nonspecific environmental factors. It affects an approximately 358 
million people worldwide, causing a significant burden on healthcare systems. The 
highest prevalence of asthma has been found in the United Kingdom (15%) fol-
lowed by Australia (14.7%), Canada (14.1%), and the United States (10.9%). In Asia 
the highest incidence of asthma has been recorded in Japan (6.7%), followed by Iran 
(5.5%), Pakistan (4.3%), Bangladesh (3.8%), and India (3%) and lowest in China 
(2.1%) [1]. It is a complex multifactorial disorder with various predisposing factors 
in environment and genes in which genetics of the individual plays a vital role [2]. 
Genome-wide studies have reported different loci that are associated with asthma. 
Asthma is associated directly with genes such as heterogeneity in Fc epsilon recep-
tor 1 (FcєR1) on 11th and q region of 5th chromosome 11, while some other gene 
polymorphisms have no direct link with asthma.
Asthma usually starts in infancy or young age. Wheezing in early childhood does 
not always lead to asthma in late childhood. As a matter of fact, wheezing in infancy 
is commonly related to those children whose airways are relatively small than nor-
mal children. They will likely wheeze when they have viral bronchitis. On the other 
hand, pulmonary function starts off at normal range in children who frequently 
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progress to asthma. After asthma development, their lungs will not develop due to 
continuous inflammation of their disease.
After genetics, another factor is the environment in which atopy is the most 
critical cause of asthma. Most of the asthmatic persons have had skin allergy in 
childhood followed by nasal allergy which leads to asthma. This series of events is 
called allergic march. Other factors in environment such as construction designs 
of houses, pollution, dust mites, molds, pet denders, particles of cockroach waste, 
tobacco smoke, inhalation of cold and dry air, food and infection are trigger 
factors to cause asthma. Today, our residence and daily activities have changed 
such as homes are more heated as well as isolated. Taking a bath and showers more 
frequently leads to more moisture inside the homes. These changes have made our 
house environment friendlier for house dust mites. Diet has also changed such as 
seasonal fruits and vegetables switched to artificially ripened fruits. This simulated 
ripening of fruits may alter their chemical structure and antigenicity [3]. Air 
pollutants that have been rising due to vehicular traffic are ozone, particulates, and 
nitrogen oxide. Air pollutant affects asthma by increasing IgE production, imposing 
oxidative stress on airways directly and indirectly, functioning as a vector for aller-
gens, and enhancing release of IL-4 and histamine from basophils [4] (Figure 1).
There is a close relationship between infections and asthma exacerbation. 
Increased exposure to infection of respiratory viruses is protective against asthma 
development. This is called hygiene hypothesis. Different researches on children 
revealed protective effect of infections in farming communities. Infants who 
drink unpasteurized milk or are taken to the animal house have a reduced chance 
of allergy and asthma, but there is no protective effect of infections if children 
are exposed only after 1 year of age. Once asthma is developed, viral diseases can 
Figure 1. 
The role of atopy and other environmental factors in asthma.
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exacerbate its symptoms because viruses increase airway inflammation linked with 
asthma. Bacterial and parasitic infections can minimize the risk of allergy by reduc-
ing IgE sensitization and weakening the airways’ response to allergen [5].
1.1 Classification of asthma
Asthma is a complex heterogeneous disease with variety of phenotypes. A dis-
ease phenotype gives information about clinical and morphological characteristics 
of disease, triggers, and therapy response but does not describe about pathogenesis 
of disease. Due to this reason, the classification of asthma has been further clarified 
with the development of endotypes, which is based on pathological mechanisms 
and treatment responses of asthma.
There is an overlap in this classification. Each endotype of asthma can have 
several phenotypes, just as a specific phenotype may be linked with more than 
one endotype [6]. These phenotypes have distinct subtypes based on symptoms, 
triggers, age at onset of disease, severity of disease, and underlying inflamma-
tion. Traditionally, asthma has been classified into extrinsic/atopic and intrinsic/
nonatopic asthma. Atopic asthma starts in children who have family members with 
history of allergy and good treatment response. Atopic asthma usually begins after 
allergen exposure. On the other hand, intrinsic asthma is developed in adult age, 
and family history is absent in this type of asthma. Intrinsic asthma is a nonallergic 
type of asthma caused by cold, humidity, strong smells, infections (viral-induced 
asthma), and chemicals in smoke and cigarette. Nonallergic asthma occurs in 
10–33% of asthmatic patients [7].
Asthma can also be divided into early-onset and late-onset asthma according to 
age of presentation of disease. Symptom-based asthma includes chronic asthma, 
acute severe asthma, brittle asthma, nocturnal asthma, and exercise-induced 
asthma. On the basis of frequency and severity of symptoms, the Global Initiative 
for Asthma (GINA) has classified asthma into intermittent, mild persistent, 
moderated persistent, and severe persistent asthma [8]. The American Thoracic 
Society and European Respiratory Society have also classified asthma into refrac-
tory asthma and “difficult/therapy-resistant asthma” based on the medication plan 
to achieve good control on asthma [9]. The World Health Organization (WHO) 
divided severe asthma into untreated severe asthma, difficult-to-treat asthma, and 
treatment-resistant severe asthma [10]. Based on etiology and underlying inflam-
mation, asthma has also been classified into eosinophilic and non-eosinophilic 
(neutrophilic and paucigranulocytic) asthma [11].
1.2 Eosinophilic asthma
Eosinophilic asthma is a specific phenotype of asthma that is defined by inflam-
mation of the basement membrane in the airway mucosa and high eosinophil levels 
in sputum and blood compared with non-eosinophilic asthma where no typical 
thickening of the basement membrane has been seen. Repeated asthma exacerba-
tions are more noticeable in patients of eosinophilic than non-eosinophilic asthma 
[12]. Even though the exact incidence of eosinophilic asthma is not known, among 
patients with severe asthma who show about 5–10% of the asthmatic people, 
sputum eosinophilia (≥2%) or blood (≥300 cells/μl) can be observed in 32–40% of 
population which are linked with recurrent asthma exacerbations, as well as disease 
severity [13]. A subgroup of patients of eosinophilic asthma maintains constant air-
ways and sputum eosinophilia even with conventional corticosteroid therapy called 
steroid-resistant eosinophilic asthma. In different studies, the levels of eosinophil in 
sputum are high in asthmatics with severe disease [14].
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Eosinophilic asthma has three distinct presentations. The first phenotype of 
eosinophilic asthma is termed as allergen-exacerbated asthma in whom patients 
show allergen sensitization (atopy), accompanied with allergic rhinitis, present 
with exacerbated symptoms on allergen exposure and common in early-onset 
asthma [7, 15]. The second phenotype of eosinophilic asthma comprises those 
individuals in whom the eosinophilic inflammation is a prominent pathology, but 
these patients are nonatopic and can present at any age especially in adult age. This 
phenotype is called idiopathic eosinophilic asthma [7, 16]. Aspirin-exacerbated 
respiratory disease is the third phenotype of eosinophilic asthma with distinct 
features comprised of the presence of severe rhinosinusitis with nasal polyps 
and aspirin sensitivity. Like idiopathic eosinophilic asthma, aspirin-exacerbated 
respiratory disease is also presented in adulthood and nonatopic patients. However, 
different studies have documented that a small number of patients who developed 
asthma early in life showed 36% tissue eosinophilia, in comparison with the late-
onset asthma which had 63% eosinophil level [17].
2. Pathophysiological mechanism
Asthma is a complex disease characterized by different pathological mechanisms 
including inflammation, hyperresponsiveness, remodeling, and angiogenesis of 
airways (Figure 2).
2.1 Airway inflammation
Eosinophilic airway inflammation is the main pathophysiological mechanism 
of eosinophilic asthma. Eosinophilic asthma develops from complex immunologic 
and pro-inflammatory mechanisms, mainly driven by T helper 2 (Th2) cells, which 
is a part of adaptive immunity release interleukins (IL-5, IL-4, and IL-13). Besides 
being orchestrated by mechanisms of adaptive immunity, Th2-mediated airway 
eosinophilia can be also linked with innate immunity, which relied on intercellular 
connection comprising of dendritic cells, bronchial epithelial cells, and innate 
lymphoid cells. As a result, airway eosinophilia arises due to the biological activ-
ity of both type 2 helper T (Th2) and type 2 innate lymphoid (ILC2) cells, which 
are critically participating in the pathogenic process of type-2 inflammation in 
eosinophilic allergic and nonallergic asthma [18]. These mechanisms are linked 
with increased IgE expression. In eosinophilic asthma patients, eosinophils collect 
in the respiratory tract. Differentiation of Th2 lymphocytes needs the association 
of various promoting elements, including costimulatory molecules and interleukins 
released by dendritic cells and inflammatory cells.
Eosinophilic allergic asthma is caused by aeroallergen like pollen and house dust 
mite which have proteolytic characteristics and also have small amount of bacterial 
components like lipopolysaccharides (LPS) [19]. Thus, on entrance into the respira-
tory epithelial membrane, allergens can attach with the Toll-like receptor (TLR), 
a receptor which is involved in innate immunity. Upon TLR activation, epithelial 
cells produce cytokines including thymic stromal lymphopoietin (TSLP), IL-25, 
and IL-33 which are capable of developing adaptive immune response of Th2 type. 
Moreover, TLR activation also evokes the secretion of chemokines such as CCL2 and 
CCL20, which increase the maturation of dendritic cells [20]. These dendritic cells 
move into the lumen of airways, take aeroallergens, and break them in the cyto-
plasm, leading to the generation of peptide fragments of allergen. These fragments 
are presented by class II HLA molecules on dendritic cells that move to regional 
lymph nodes where these antigen fragments are presented to T lymphocytes [21].
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After activation of T-cell receptors by antigenic peptides, sensitization and 
stimulation of adaptive immune system take place. Stimulation of naive T lym-
phocytes needs the attachment of their costimulatory molecules (CD28, ICOS, and 
OX40) with their ligand present on dendritic cells (CD80/B7.1, CD86/B7.2, ICOS 
ligand, and OX40 ligand). Differentiation of T lymphocytes is critically dependent 
on the cytokine environment [22]. Th2 polarization requires high levels of IL-4 and 
low concentration of IL-12. IL-4 is secreted by mast cells and basophils. GATA3 
is the main transcription factor present in type 2 helper T cells that promote the 
production of Th2-type cytokines including IL-4, IL-5, IL-9, and IL-13. These inter-
leukins cause eosinophils and mast cells’ maturation and recruitment, promoting 
immunoglobulin class switching to IgE production. As a result, cytotoxic products 
released by degranulation of eosinophils induce airway epithelial injury, mucus 
hyperproduction, bronchial hyperresponsiveness, impaired ciliary movement, and 
an increase in smooth muscle size [23].
The late-onset type of eosinophilic asthma that is usually nonallergic arises in 
the absence of stimulation of Th2 lymphocytes. Recent researches suggest that the 
main role in the development of eosinophilic nonallergic asthma is played by 
Figure 2. 
Pathogenesis of eosinophilic asthma. Asthma arises from interaction between genetic and environmental factors 
including allergens and viruses. Allergens or viruses can be caught by dendritic cells (DCs) located in the 
epithelium, which process and present antigen to naive (Th0) T helper cells. This allergen activates Th0 to Th2 
cells which produce IL-4 and IL-13. These cytokines activate B cell for class switching to IgE immunoglobulin. 
Further, Th2 cells also secrete IL-5, which activates and recruits eosinophil. IgE-dependent degranulation of 
mast cells secretes both immediate and newly formed mediators like leukotriene, prostaglandin cytokines, etc. 
other important cells contributing to asthma pathobiology are type 2 innate lymphoid cell (ILCs2), producing 
IL-13 and IL-5 which cause eosinophil recruitment and expansion in nonallergic eosinophilic asthma.
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ILC2s which is activated by IL-25, by IL-33, and by prostaglandin D2 (PGD2) [24]. 
Consequently, these two distinct pro-inflammatory routes driven by either Th2 
lymphocytes or innate ILC2s produce IL-5 which is mainly involved in eosinophilic 
inflammation of airways in asthma.
2.2 Airway hyperresponsiveness
Chronic inflammation of airways in asthma leads to more rapid contraction 
of smooth muscles of airways than in normal person in effect of broad range of 
stimuli, a condition termed airway hyperresponsiveness [25]. Airway hyperrespon-
siveness is a result of eosinophil infiltration mediated by T lymphocyte-secreted 
factor called eosinophil chemotactic factor (ECF-L). Hyper responsiveness of the 
air ways is caused by the decrease in function of neuronal M2 muscarinic recep-
tor on parasympathetic nerves in the lungs due to eosinophil’s major basic protein 
which is a protein released from granules of eosinophils. Schwartz et al. reported a 
direct relationship between eosinophil count in the airways, sputum and peripheral 
blood, and airway hyperresponsiveness [26].
2.3 Airway remodeling
Airway remodeling is the permanent cellular and structural modification in the 
airways primarily due to repair mechanisms in reaction to chronic inflammation. 
In a broad term, the airway is modified so that it acts in a different manner when 
allergens or nonspecific factors like exercise, cold air, perfume, and smoke are 
induced into the patient and it leads to irreversible change of lung functions [27]. 
There are various changes in structural and physiological characteristics which are 
different in every asthmatic patient. Most noticeable structural change is thickening 
of basement membrane of airway which is due to accumulation of type III col-
lagen produced by myofibroblast. These myofibroblastic cells are stimulated and 
controlled by growth factors secreted by the epithelial cells and various cytokines 
(transforming growth factor-β (TGF-β), IL-10, and IL-17) released by T lympho-
cytes and eosinophils that have profibrotic responses while at the same time down-
regulating the function of T and B lymphocytes [28].
Previously, it was thought that the airways’ epithelial membrane is an innocent 
sufferer, becoming injured and lost due to the effect of toxic agents secreted by 
eosinophils and other inflammatory cells. But now, it has been reported that growth 
factors and interleukins (IL-8) secreted by the cells of epithelial membrane perform 
an active role in remodeling. Metalloproteases and epidermal growth factors released 
from matrix on inflammation stimulate these chemokines. On chemokine activation, 
neutrophils and other immune cells attracted to the area of damage cause structural 
alterations in the airways. Other structural changes including mucus metaplasia and 
increased angiogenesis have also been observed in asthmatic patients [29].
2.4 Angiogenesis
There is a rise in the number of blood arteries in the medium and small respiratory 
airway submucosa. It may help in physiological changes in airways of patients with 
asthma, including asthma due to exercise. Several studies have been documented 
that vascular endothelial growth factor (VEGF) may contribute in angiogenesis. 
High expression of VEGF has been observed due to hypoxia and several cytokines 
and growth factors such as epidermal growth factor, TGF-β, IL-1α, and IL-6. VEGF 
expression is decreased by other interleukins including IL-10 and IL-13 [30].
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2.5 Role of eosinophil in pathogenesis
Eosinophils are granulocytes in blood produced in the bone marrow with other 
white blood cells making about 1–3% of white blood cells. Eosinophil plays multiple 
functions and is an important component of allergic and asthmatic type 2 immune 
responses. Allergens on exposure starts a group of processes by Th2 cytokine-
producing cells, resulting in eosinophils’ attraction to the airway through the action 
of IL-5, and eotaxin research reported that Clara cells of the airway epithelium are 
the main source of eotaxin in the lung [30].
During asthma attack, eosinophils are stimulated to release proteins from 
granules including major basic protein, eosinophil peroxidase, eosinophil cationic 
protein, and eosinophil-derived neurotoxin, all of which are toxic to the epithelial 
cells of airway. Furthermore, eosinophils secrete plenty of inflammatory media-
tors like cytokines (interleukins IL-13 and IL-5), platelet-activating factor, growth 
factors (TGF-α and TGF-β), leukotrienes, thromboxane, and prostaglandins. 
The secretion of all these mediators results in enhancement of the inflammatory 
process, airways’ epithelium cell injury, airway hyperresponsiveness, mucus hyper-
secretion, and airway remodeling and bronchospasm [31]. Eosinophils control the 
allergen-dependent Th2 pulmonary immune responses activated by dendritic cells 
and T cells as well as decrease Th1 responses [32].
2.6 Role of IL-5 in pathogenesis
Although various bioactive proteins such as IL-3 and granulocyte-macrophage 
colony-stimulating factor affect the life cycle of eosinophils, eosinophils react 
mainly to IL-5. Th2 cells, ILCs2, mast cells, natural killer T (NKT) cells, and 
eosinophils produce IL-5 within respiratory air passage of sufferer with eosinophilic 
asthma. In asthmatic patients, the bone marrow responds to environmental irritant 
by rising eosinophil production, and in asthmatics presenting both acute and late 
asthmatic reactions, this event is related with increased IL-5 mRNA proportion 
than persons having only early bronchial reactions. Apart from the effect of IL-5 on 
the bone marrow, it has also been observed that IL-5 enhances eosinophil matura-
tion in airways of allergic patients [33].
IL-5 can also promote eosinophilic infiltration in bronchial airways due to 
synergetic effect of IL-5 with other chemoattractants of eosinophils such as eotax-
ins. The IL-5 role in eosinophil recruitment within the bronchial airways is due to 
its antiapoptotic action on eosinophils [34]. IL-5 exerts its effect by attachment with 
IL-5 receptor expressed on eosinophils and basophils. IL-5 receptor is composed 
of an IL-5-specific α subunit (IL-5Rα) and a nonspecific βc chain that react with 
IL-5, IL-3, and GM-CSF [35]. The level of IL-5Rα is expressed three times higher on 
eosinophils than basophils [36].
2.7 Role of IL-33 in pathogenesis
IL-33 is the newly discovered member of cytokine of IL-1 group. Schmitz 
et al. described IL-33 as a promoter of various type 2-related responses, includ-
ing cytokine (IL-4, IL-5, and IL-13) and IgE production. In addition to type 
2-related response, ST2, the IL-33 receptor, is present on several types of cells 
engaged in type 2 effector function, including Th2 cells, mast cells, basophils, 
eosinophils, and ILC2s [37]. Studies in asthma described the supporting role of 
IL-33 on monocyte development and eosinophil differentiation from the bone 
marrow [38].
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2.8 Role of mast cell pathogenesis
Mast cells are the source of the Th2 cytokines including IL-4 and IL-5 that 
regulate antibodies’ class switching to IgE and eosinophil production, respectively. 
Mast cells have been observed in higher frequency in asthmatic airways and stimu-
lated by allergen exposure. On activation, mast cells degranulate and secrete their 
mediators such as histamine and leukotrienes, causing bronchospasm and acute 
bronchoconstriction by allergen. On the other hand, leukotriene is an essential 
mediator in airway inflammation and remodeling specifically in symptoms induced 
by exercise in intrinsic asthma. The granule proteases including tryptase are also 
released by mast cells. Tryptase is involved in airway remodeling and releases pro-
inflammatory chemokine from intracellular matrix [39].
2.9 Role of ILCs in pathogenesis
Innate lymphoid cells (ILCs) are newly discovered immune cells that have 
lymphoid morphology but deficient in antigen receptor. Type 2 innate lymphoid 
cells (ILC2) are non-B/non-T cells that release IL-5 and IL-13 on activation by IL-25 
and IL-33 and expressed MHC class II high and CD11cdull on their surface. Several 
studies reported that ILC2 originates from common lymphoid progenitor cells and 
not from either myeloid or erythroid progenitors, confirming that these cells are of 
lymphoid origin. ILCs have three different types, ILC1s, ILC2s, and ILC3s, on the 
basis of identical cytokine profile associated with the helper T subsets Th1, Th2, 
and Th17, respectively [40]. ILC2s are known to produce type 2 cytokines including 
IL-4, IL-5, and IL-13 on exposure to allergen, IL-25 and IL-33, and are therefore 
probable new member in Th2 cell-independent innate type 2 responses. ILC2s can 
be stimulated by several cytokines especially epithelial cell-derived cytokines IL-25, 
IL-33, prostaglandin, and leukotriene which have been observed to start ILC2 reac-
tion in both animals and humans [41].
3. Diagnosis
Eosinophilic asthma diagnosis is considered essential in primary, secondary, and 
tertiary treatments. Typically, general practitioner uses this diagnosis to determine 
the initialization of inhaled corticosteroids (ICSs). A patient with signs of eosino-
philic inflammation is likely to respond to ICSs; however, patients should not be 
treated with ICSs in the absence of airway eosinophilia. In addition, it is essential 
to recognize if a patient has airway eosinophilia because those with chronic eosino-
philia are susceptible to severe problems and airway remodeling in spite of inhaled 
or oral corticosteroid treatment. Therefore it must be completely examined [42]. 
Significantly, all available resources and information are used in all settings to bet-
ter presume if a person has eosinophilic asthma.
Eosinophilic asthma analysis depends on the confirmation of eosinophilic 
inflammation in airways of asthmatics, though there is no common diagnostic 
method. Many procedures can be utilized to diagnose airway eosinophilia in the air-
ways that include induced sputum, bronchial biopsies, blood, and exhaled breath. 
Generally, airway biopsies or bronchoalveolar lavage (BAL) is principally observed 
for the analysis of airway inflammation. But for daily clinical use, this method is 
very invasive. Hence, to determine airway inflammation aseptically in an appropri-
ate and cheap manner. The best recognized and the most common method for test-
ing eosinophilic asthma is the identification of eosinophils in induced sputum [43].
9Eosinophilic Asthma
DOI: http://dx.doi.org/10.5772/intechopen.84297
3.1 Bronchial mucosal and BAL eosinophils
The histocytology of a biopsy sample of bronchial tissue could be a diagnostic 
test to determine the appearance of eosinophils in the submucosa and epithelial 
cells of air passage. But in daily clinical use, it is impossible to take patients’ 
biopsy due to an invasive method. The interaction between eosinophils is poor in 
different airway areas because BAL represents eosinophils in the peripheral air 
passage, while sputum wash and bronchial wash produce a variety of small and 
adjacent large air passages. Additionally, the analysis of bronchial submucosal and 
BAL eosinophils is not consistent, so it is difficult to relate results of these tests 
between laboratories. Roughly, if the tissue and BAL express sufficient amount of 
eosinophil, possibly they are also increased in sputum. This observation may not 
be true. More importantly, the number of eosinophils in sputum (airway luminal) 
is more associated with clinical guidelines for asthma control, like the worsening 
of symptoms than the numbers of eosinophils in tissue section. This associa-
tion may not be surprising, provided that eosinophils are triggered as they pass 
through different areas and are further induced in the lumen of air passage than 
in tissues [44].
3.2 Eosinophil count in sputum
The advance applications of methods to carefully and accurately induce and 
assess the sputum have allowed the possibilities to investigate the features of 
inflammatory process in airway in asthmatics. This brings attention to the heteroge-
neity of airway inflammation in asthma [45]. Currently, sputum analysis is essen-
tially an extensive and aseptic method for testing the airway inflammation. The 
analysis of sputum with hypertonic solution of saline is reliable in asthmatics who 
have just 0.9 L forced expiratory volume in the first second (FEV1) and is effective 
in almost 80% of asthma patients [46]. The test for the collection, preparation, 
and determination of cell counts of sputum is easily characterized and organized, 
and its stability, responsiveness, and validity were explained. The normal values 
for sputum cell counts were determined, and on the basis of sputum examination, 
guidelines are available to improve the treatment. However, the eosinophil count in 
non-asthmatics is 1.2%, while 3% or more sputum eosinophil is usually believed as 
clinically important. Further investigation is required apart from the complete cell 
differentiation, probably the levels of biomarkers, like eosinophil-free granules, or 
the level of protein released from granules (e.g., eosinophil peroxidase) is precise 
and more significant [47].
3.3 Peripheral blood eosinophil
Eosinophilic counts in a peripheral blood are easily collected and mostly con-
venient, and still it is deficient in both accuracy and susceptibility. However, some 
asthmatics perhaps reveal that blood eosinophils rise in those patients who have 
peripheral eosinophilia. So a proposed association is found with acute asthma signs 
and decreased pulmonary activity as examined by FEV1 [48]. But in asthma, blood 
eosinophil counts were not recognized to safely associate with increased eosinophils 
in sputum. It was shown that eosinophils’ quantity (>300/μL) in blood had just 
50% positive predictive value in finding the phenotype of an asthma that is on the 
basis of eosinophil in sputum (>2%). Altogether, these studies show that peripheral 
blood eosinophilia perhaps is a sign of severe condition in asthma but not constantly 
associated with sputum eosinophilia.
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3.4 Pulmonary function test (PFT)
PFT evaluates volume and rate of airflow that breathe in and out. The FEV1 of 
exhalation is assessed and compared to the total air volume during forced expiration 
(forced vital capacity [FVC]). It is an early test for diagnosis of asthma to evaluate 
airway blockage, disease severity, and reversibility of symptoms. Reduced FEV1, 
blockage in airflow (lower level of FEV1/FVC), and concavity in FEV loop are 
expected in patients of asthma [49]. Other PFTs include bronchodilator respon-
siveness (BDR) test which is predictive of adult-onset asthma. Specific airway 
resistance (sRaw) analyses by body plethysmography may also be an indicator of 
early airflow blockage. Hastie et al. reported multiple parameters such as FeNO 
level, reduced FEV1, persistent airflow obstruction, total IgE, and blood eosinophil 
counts in diagnosing eosinophilic asthma [50].
3.5 Exhaled breath condensate (EBC)
EBC is a new, noninvasive test of identifying biological markers, predominantly 
secreting from the lower part of the airway. EBC is obtained at the time of quiet 
respiration, as a result of cooling and liquefaction of the air droplets that breathe 
out [51]. It is a distinct method in detecting molecular pathways related to the 
respiratory tract. Antus et al. reported lower EBC pH in asthmatic compared with 
control subjects [52]. Hydrogen peroxide (H2O2), an indicator of oxidative stress, 
was elevated in EBC of patients with asthma. Furthermore, EBC-H2O2 concentra-
tion is associated with asthma severity and prognosis [53]. Other biomarkers such 
as CysLTs (LTD4, LTE4, and LTC4), eicosanoids (8-isoprostane and prostaglandin 
E2), interleukins (IL-4), and high-sensitivity C-reactive protein (hs-CRP) are found 
in increased levels in asthma with exercise-induced bronchoconstriction. Serum 
hs-CRP and fractional exhaled nitric oxide (FeNO) concentration were significantly 
associated with EBC-hs-CRP levels in patients of asthma [54, 55].
3.6 Fraction of exhaled nitric oxide (FeNO)
Nitric oxide synthase helps in the synthesis of nitric oxide, a reactive molecule 
that is shown on cells in airway epithelium. In asthma, FeNO analysis by breath 
assays is usually treated as an aseptic sign of airway inflammation. FeNO analysis is 
simple, rapid, and noninvasive in contrast to the bronchoscopy and sputum induc-
tion. Significantly, it was shown that FeNO quantification perhaps is helpful as a 
clinical instrument for administering the asthma and managing the disease, but 
different findings result in some controversy about FeNO efficacy [56]. In a study, 
more than 90 asthma patients were examined by Smith et al., and they identified 
that FeNO acts as an effective tool for the withdrawal of inhaled corticosteroid 
treatment. Tseliou et al. also studied that >19 parts per billion FeNO levels were due 
to sputum eosinophilia with 78% sensitivity and 73% reactivity in individuals who 
had mild to acute asthma, while few of them relied on prednisone. Differently, Nair 
et al. in a clinical trial performed with mepolizumab described that FeNO levels and 
sputum eosinophil percentages are not associated with asthmatics who relied on 
prednisone [57].
3.7 Total IgE
IgE plays an important part in allergic asthma. IgE antibodies produced by 
allergic patients are specific for antigens like pollens and house dust mite, attached 
with IgE-specific receptors on basophils and mast cells. The connection of IgE 
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molecules stimulates the release of intermediates (arachidonic acid metabolites and 
histamine) and cytokines (IL-4, tumor necrosis factor alpha, and IL-5) that are 
important for early- and late-stage allergic response and the associated penetration 
of eosinophils in the airway. Different findings which have determined a relation 
between levels of IgE in serum, airway eosinophilic asthma, and anti-IgE treatment 
were explained, closely related with a remarkable decrease in tissue eosinophils. But 
in spite of these findings, it is not suggested to use IgE as a biomarker for eosino-
philic inflammation. Latest meta-analysis by Korevaar and his fellows, they have 
described low validity and inadequacy for this biomarker in comparison with FeNO 
to find sputum eosinophilia [58]. The results were not valid, when comparing blood 
eosinophils with IgE. Hence, to find eosinophilic asthma, IgE appears to be less 
effective of all currently available biomarkers.
3.8 Periostin
Periostin is an interleukin-13-regulated matrix protein which is present outside 
the cells. It was described that periostin promotes the recruitment of allergen-
induced eosinophils to the lungs, leading to eosinophil binding to fibronectin. 
Additionally, it was shown that periostin affects the durability of lung cancer cells 
due to Akt/PKB pathway; though it has not been examined, maybe it could improve 
the survival of eosinophils [59].
Generally, periostin is available as an essential biomarker for the detection of 
eosinophil levels in air passage in asthma patients because of its function in the 
recruitment of eosinophils in tissue. Jia et al. conducted a study on different param-
eters that include age, BMI, gender, blood eosinophils, and levels of IgE, FeNO, and 
periostin in the serum of 59 acute asthmatic cases and demonstrated that airway 
eosinophilia was best determined by periostin in the serum. The level of periostin 
(>25 ng/mL) in serum had 93% positive predictive value and 37% negative pre-
dictive value for >3% eosinophils in sputum or tissue eosinophilia. In asthma the 
exact function of periostin is not observed. In addition to function in eosinophilia, 
animal models propose that perhaps periostin is associated with airway remodel-
ing through growth factor-β switching and can also have supportive part in airway 
hyperresponsiveness induced by allergen [60].
4. Treatment
The present eosinophilic asthma treatment is introduced with common guide-
line-based therapy that consists of ICS and bronchodilators that have been thor-
oughly studied elsewhere [61]. Usually the eosinophil appearance has been linked 
with susceptibility to corticosteroids, while some eosinophilic asthma patients were 
identified with subsequent steroid refractory.
Eosinophilic asthma treatment consists of elevated dose of ICS and oral cor-
ticosteroids. ICS are primarily used to decrease airway inflammation and mucus 
hypersecretion, beginning with the reduced strong dosage and increasing to high-
dose ICS due to increased intensity. Several severe asthmatics become addicted to 
corticosteroids. Depending upon toxic corticosteroids for long-term maintenance, 
treatment perhaps impairs the individuals and may result in corticosteroid resis-
tance [62].
Perhaps many methods which are considered for corticosteroid-resistant 
asthma have been described in addition to the activation of p38 mitogen-activated 
protein kinase and inflammatory genes controlled by transcription factor-kB. A 
p38 mitogen-activated protein kinase is significant to trigger GATA3 (the master 
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Th2 cytokine transcription factor). Moreover, phosphoinositide 3-kinase (PI3K) 
controls inflammatory pathways and activates the PI3Kδ isozyme through oxida-
tive stress that can reduce the corticosteroid susceptibility by decreased histone 
deacetylase 2 (an enzyme marked by theophylline). Further steroid refractory 
asthma can comprise elevated expression of the alternatively linked variant of the 
glucocorticoid receptor and elevated formation of macrophage migratory inhibitory 
factor that can arrest the anti-inflammatory outcomes of corticosteroids [63].
Other factors are under examination for the management of asthma comprised 
of antagonists focusing on thymic stromal lymphopoietin, IL-25, IL-33, GM-CSF, 
and chemokine receptor 3 that are expressed on eosinophils [61].
4.1 Biologic therapies
The treatment of refractory eosinophilic asthma includes the drugs that spe-
cifically target T helper 2 cytokines as well as anti-IgE, anti-IL-5, and anti-IL-13 
monoclonal antibodies [64].
4.1.1 Omalizumab
An IgG1 recombinant humanized monoclonal antibody against IgE is 
omalizumab. Omalizumab binds with IgE Fc portion, recognizing FcεR1, IgE 
high-affinity receptors on the top of basophils, and mast cells that result in the 
downregulation of receptor and suppress the release of inflammatory intermedi-
ates. An important function of IgE is to act in allergic response pathophysiology, 
while omalizumab impairs both early- and late-phase inhaled allergen responses in 
asthmatics [65]. The previous studies showed a remarkable decrease in eosinophils 
in airway tissue and induced sputum (8 at baseline in contrast to 1.5 posttreat-
ment) in asthmatics that were treated with omalizumab. Later, it was reported that 
treatment for 16 weeks reduced the number of eosinophils in blood from 6.2 to 1.3% 
at baseline [66]. Thus total serum IgE is not applicable for eosinophilic asthma as a 
diagnostic marker. So, the levels of total IgE in serum should be applied for examin-
ing anti-IgE therapy.
The therapy against IgE is effective to eosinophilic asthma treatment in spite 
of IgE levels. One reason for the observed paradox is that the no response of IgE 
levels may be associated with the downregulation of FcεR1 by anti-IgE on the 
surface of basophils, dendritic cells, and mast cells. A decrease in cells that express 
FcεR1 reduces the intermediate responses of allergen-induced IgE, suppressing 
the discharge of cytokine and the induction of eosinophil into the airway [67]. 
Moreover, anti-IgE treatment may assist to reduce the numbers of airway dendritic 
cells that result in the reduction of Th2 cell differentiation and Th2 cytokines that 
are required for the recruitment and survival of eosinophils. Thus total IgE in serum 
may not be related to clinical response or eosinophilic asthma, while omalizumab is 
useful in the treatment of asthma and decreases the airway eosinophils.
It was studied by Noga et al. that omalizumab is also important as it may have 
proapoptotic effects on eosinophils [68]. The reduced number of mast cell media-
tors helps in the stability of eosinophil that may lead to eosinophil apoptosis in indi-
viduals that were tested with omalizumab. Particularly, omalizumab is also found as 
a corticosteroid-sparing drug in persistent eosinophilic pneumonia, a condition that 
is identified by symmetric lung penetration and the remarkable eosinophil recruit-
ment in blood and BAL fluid [69]. Hence, the outcomes of anti-IgE therapy on lung 
eosinophilia give more understandings about allergic inflammation mechanisms, 
which can assist in improving the phenotype-specific analysis.
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4.1.2 Targeting IL-5 and interleukin-5 receptor α
The key function of IL-5 in tissues is to stimulate the growth, recruitment, 
activation, and differentiation of eosinophils. Initial studies described the elevated 
IL-5 expression in BAL fluid and bronchial biopsies in asthmatic patients. Moreover 
it was shown that following the allergen confront, IL-5 mRNA was regulated in 
bronchial mucosa, and the levels were associated with the disease activity. After 
anti-IL-5 treatment, airway hyperresponsiveness and airway eosinophil assembly 
after allergen challenge were reduced in animal models [70]. So, there is enough 
explanation for selecting IL-5 in asthmatics to particularly decrease the eosino-
phil migration, maturation, and stability that can cause many features of asthma 
pathogenesis.
4.1.2.1 Mepolizumab
An IgG1-humanized noncomplement-fixing monoclonal antibody is mepo-
lizumab that is specific for human IL-5. Mepolizumab prevents the binding of 
human IL-5 to the alpha chain of IL-5 receptor complex that is expressed with high 
affinity on the surface of eosinophil cell. It was shown that in the bronchial mucosa 
of atopic individuals, anti-IL-5 therapy causes maturational blockage of eosinophil 
progenitors in the bone marrow and reduces the eosinophil precursors (CD34+ 
IL-5Rα+) [71]. It is interesting that mepolizumab has different effects in different 
tissues which results in the complete reduction of eosinophils in sputum and blood 
exclusively 55% decrease in the bronchial mucosa. It was proposed by Flood-Page 
et al. that different levels of tissue infiltration could be due to the improved expres-
sion or downregulation of IL-5 receptor. Once assembled into the tissue, probably 
the survival of airway eosinophils depends on IL-3, GM-CSF, or eotaxins.
Two latest findings demonstrate that there could be useful outcome of mepoli-
zumab in certain groups of eosinophilic asthma patients. It was found that double-
blind placebo-controlled research consists of 61 cases with a history of chronic 
acute exacerbations and refractory eosinophilic asthma; following 1-year monthly 
injections of mepolizumab, a remarkable decrease in exacerbations and recovery in 
symptom scores were observed in patients treated with mepolizumab [72].
4.1.2.2 Reslizumab
Reslizumab is an anti-IL-5 humanized monoclonal antibody (IgG4), also 
provided to the eosinophilic asthma patients that were poorly managed [73]. A 
latest study described a remarkable decrease of eosinophils in sputum, and the 
respiratory activity improved while relating with inactive drug following monthly 
15 weeks of reslizumab therapy (3 mg/kg). The useful results of reslizumab were 
mostly marked in nasal polyp patients and in those patients who had a maximum 
level of eosinophils in sputum and blood. Significantly besides the level of eosino-
phils, the appearance of nasal polyposis can recognize asthma patients that were 
treated with anti-IL-5.
4.1.2.3 Benralizumab
Benralizumab is an anti-IL-5Rα afucosylated humanized monoclonal antibody, 
identified on eosinophils and nowadays in Phase II clinical trials. In a prospec-
tive Phase II study, the result of one shot of benralizumab (1 mg/kg) that was 
given intravenously related to the monthly three shots (100 or 200 mg) given 
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subcutaneously or placebo in adult patients of eosinophilic asthma was studied [74]. 
It was described that following final dose of benralizumab through intravenous and 
subcutaneous passage helped in the reduction of eosinophil levels in sputum and 
airway mucosa as well as complete eosinophil count arrest in peripheral blood 
and bone marrow for up to 28 days.
4.1.3 Targeting interleukin-4 and interleukin-4 receptor α
IL-4 and IL-13 are essential cytokines in the pathogenesis of atopic disease and 
allergic asthma. These are expressed by basophils, innate lymphoid cells, mast cells, 
and Th2 cells. IL-4 is important for various asthma characteristics that include 
mucus formation, switching of B-cell isotypes, and differentiation of Th2 cells. IL-4 
and IL-13 transmit signal inside the cells by two different overlapped heterodimeric 
receptors which are part of IL-Rα [75]. Receptor attachment is triggered by a typical 
signaling pathway, signal transducer and activator of transcription 6 (STAT-6), 
that is important for the production of Th2 inflammation, an asthma feature. 
Significantly, eotaxins help in eosinophilic induction as well as rely on IL-4 or IL-13 
for the stimulation of STAT-6. At present many drugs are under examination that 
use IL-4/IL-13/STAT-6 pathway.
4.1.3.1 Pascolizumab
Pascolizumab is a human-based IL-4 monoclonal antibody that was considered 
in animal studies as well as Phase I and II clinical trials. Pascolizumab was strongly 
accepted in Phase I clinical trial with mild to moderate asthma in adult patients; 
anyhow following Phase II trial on a large scale was stopped because it was unsuc-
cessful to express the clinical results in symptomatic individuals who were steroid 
immature [76].
4.1.3.2 Altrakincept
Altrakincept is an artificial humanized antagonist IL-4Rα that inhibits the 
penetration of airway eosinophils and hypersecretion of mucus in a mouse model 
when managed during allergen challenges. One dose of the medicine improves the 
pulmonary activity and disease problems in Phase I and II trials [77].
4.1.3.3 Pitrakinra
Pitrakinra is an antagonist, which targets the heterodimeric receptor of IL-4 and 
IL-13 cytokines, comprises the subunits IL-4Rα and IL-13Rα1. Pitrakinra sup-
pressed the early-stage and late-stage reactions produced by allergen when managed 
by the subcutaneous or inhaled passage [78].
4.1.3.4 Dupilumab
A humanized monoclonal antibody to the IL-4Rα subunit is dupilumab, 
currently described in a follow-up study analysis [79]. It was studied that 104 
subjects with mild to acute persistent asthma and eosinophilia were separated to 
gain subcutaneously a single dose (300 mg) of dupilumab or placebo in a week 
for 12 weeks. In the treated group, this study developed a remarkable recovery 
in lung function related to the decrease in asthma inflammation as long-acting 
beta-agonists, and received steroids were absorbed. In addition, the significant 
modifications from basic standards in Th2-related indicators, as well as FeNO, 
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IgE, chemokine ligand 17, and chemokine ligand 26 (eotaxin-3), were found in 
the group of dupilumab by 12 weeks. The levels of blood and sputum eosinophils 
were not dissimilar following dupilumab therapy, while there were less number 
of people who give sputum, so statistical examination was excluded. Generally, 
identifying the IL-4Rα signaling (that also stimulates IL-13 signaling) acts as a 
good therapeutic approach for eosinophilic asthma.
4.1.4 Targeting IL-13
An important part of IL-13 in airway eosinophilic induction in a way depends 
on the combined function of IL-5 and eotaxin in mouse models. Additionally, many 
studies demonstrate that IL-13 is important for corticosteroid protection in asthma. 
In a study on animals, IL-13 inhibition procedures have described reduction in 
airway hyperresponsiveness, inflammation caused by environmental immunogen, 
and remodeling of airways [80]. Thus nowadays, pharmaceuticals that target this 
cytokine are under examination in those who have refractory eosinophilic asthma 
due to steroids.
4.1.4.1 Anrukinzumab
Anrukinzumab is a complete human IL-13-targeted antibody. In Phase II clinical 
trial, its effects have shown a decrease in late asthmatic responses produced by 
allergen after two doses (2 mg/kg) that were given subcutaneously for 2 weeks [80].
4.1.4.2 Lebrikizumab
Lebrikizumab is a humanized anti-IL-13 monoclonal antibody. In a latest 
study, lebrikizumab was investigated in 219 adults with weakly controlled asthma 
against long-acting beta-agonists and ICSs [81]. Consequently, the treated group 
after 12 weeks of therapy has improved FEV1, while high pretreatment with serum 
periostin levels has more good effects in patients. In post hoc examination, it was 
interesting that high FeNO and Th2 markers which include CCL13 (human mono-
cyte chemoattractant protein-4), peripheral eosinophilia, CCL17, and total IgE 
levels were further related with a significant decrease in the levels of acute problems 
in lebrikizumab-treated cases relative to placebo.
4.1.4.3 Tralokinumab
Tralokinumab is another antibody against IL-13, also effective in Phase II study 
in improving the lung activity of individuals with moderate to acute asthma [81].
5. Conclusions
In conclusion, asthma is a heterogeneous condition with several phenotypes and 
endotypes on the basis of different immunopathogenic mechanisms such as under-
lying inflammation, environmental factors, and disease severity. Understanding 
of distinct phenotypes with specific pathophysiology is essential for management 
of patients with eosinophilic asthma. Categorization of asthma into eosinophilic 
and non-eosinophilic subphenotypes depends on the difference in cells involved in 
inflammation of respiratory airway. Generally, eosinophilic inflammation has been 
linked with extrinsic (allergic) asthma with Th2-type response, but now eosino-
phils have also been observed in the airways of nonallergic (intrinsic) asthma. The 
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development of new biological therapies like monoclonal immunoglobulin and 
small particles that block IgE, interleukins of Th2 type, and particular inflam-
matory factors has improved the knowledge about the immunopathogenesis of 
this phenotype and emphasizes the significance of individual-directed treatment. 
For doctors, it is essential to early recognize eosinophilic patients because this 
phenotype may need patient-directed therapies to prevent worsening of asthma 
symptoms.
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